Plus   Neg

Global Payments To Buy Zego From Vista Equity For $925 Mln Cash

Payment technology company Global Payments Inc. (GPN) has decided to acquire property technology company Zego from Vista Equity Partners, in an all cash transaction valued at $925 million, the company said in a statement.

The effective purchase price, excluding a tax asset, is about $830 million.

"This acquisition aligns perfectly with Global Payments' strategy by enhancing our position at the convergence of software and payments in one of the largest and most attractive vertical markets worldwide, where digital commerce and omni-channel trends are rapidly accelerating," said Cameron Bready, Global Payments President and Chief Operating Officer.

Zego's solutions support property managers and residents throughout the real estate lifecycle, from leasing and onboarding to one-time and recurring payments, work orders, utility management, resident communications, renewals, and offboarding.

Zego's real estate technology platform is being used by nearly 7,000 property management customers representing more than 11 million residential units in the United States. Through its integrated payments offering, Zego facilitates nearly $30 billion in payments, a year, in a market with volume opportunity exceeds $1 trillion, Global Payments said.

The deal is expected to close by the end of the second quarter of 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Fashion retailer L Brands, Inc. announced Tuesday that its Board of Directors has unanimously approved a plan to separate the company into two independent publicly traded companies. The two public companies will be Bath & Body Works, one of the world's leading bath, body and home fragrance retailers, and Victoria's Secret, including Victoria's Secret Lingerie, PINK and Victoria's Secret Beauty. Danish pharmaceutical company Novo Nordisk A/S is recalling 1,468 product samples of Levemir, Tresiba, Fiasp, Novolog and Xultophy to the consumer level, due to improper storage temperature conditions, the U.S. Food and Drug Administration said. The Food and Drug Administration on Monday expanded the emergency use authorization of Pfizer-BioNTech's Covid-19 vaccine to include 12- to 15-year-olds. "The FDA's expansion of the emergency use authorization for the Pfizer-BioNTech COVID-19 Vaccine to include adolescents 12 through 15 years of age...
Follow RTT